and polyoxyethylene(20) sorbitan monolaurate (Tween 20) including antitumor drugs such as 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) have been observed on the growth of glioma cells in vivo [6] . On the other hand, HL composed of DMPC and polyoxyethylene(n)dodecyl ethers (C 12 (EO) n ) without any drugs have remarkable inhibitory effects on the growth of various tumor cells including leukemia, lymphoma and colorectal cancer along with apoptosis in vitro [7] , in vivo [8, 9] and clinical applications [10, 11] .
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In this study, we examined the inhibitory effects of hybrid liposomes (HL) composed of DMPC and C 12 (EO) 25 on the growth of human prostate cancer cells in vitro.
Hybrid liposomes (HL) are nanosized liposomal particles (Figure 1 A) and can be prepared by sonication of a mixture containing 90 mol% DMPC (NOF, Japan) and 10 mol% C 12 (EO) n (n = 25: Nikko Chemicals, Japan) in 5% glucose solution as described previously [12] . The liposomes composed of DMPC alone (DMPC liposomes) were prepared in the same manner as described above. The sample solutions were sterilized using a membrane filter with 0.20 μm pore size. Figure 1B shows the time course of the hydrodynamic diameter (d hy ) change for HL using an electrophoretic light scattering spectrophotometer (ELS-Z, Otsuka Electronics, Osaka, Japan). The mean d hy of HL was about 33 nm in diameter with a single and narrow distribution and was stable for 35 days, though d hy of DMPC liposomes gradually increased with time. It is worthy to note that HL having size under 100 nm in diameter could avoid the reticular endothelial system in vivo [13] and thus should be appropriate for the intravenous administration in vivo and clinical applications.
First, we examined the 50% inhibitory concentration (IC 50 ) of HL on the growth of human prostate (DU145 and PC-3) cancer cells with WST-8 assay [12] [13] [14] . The cells (5.0 × 10 4 viable cells/ ml) were seeded into 96 well plates and incubated for 48 hrs in humidified 5% CO 2 at 37°C in the presence or absence of HL. Subsequently, the WST-8 solution (Dojindo Laboratories, Japan) was added to each well. After 3 hrs, the absorption at 450 nm was measured with VersaMax Microplate Reader (Molecular
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Introduction
Prostate cancer occurs when malignant cells form in the tissues of prostate. Hormone therapy, also known as androgen deprivation therapy, can be used to treat prostate cancer after surgery or radiation therapy [1] . However, hormone therapy alone does not eradicate prostate cancer and metastatic prostate cancer does not respond to hormone therapy or chemotherapy [2] . Thus, the development of a new chemotherapeutic agent for prostate cancer is urgently needed [3, 4] .
Hybrid liposomes (HL), first developed by Ueoka et al. [5] , can be prepared by simply ultrasonicating a mixture of vesicular and micellar molecules in buffer solutions, and contains no organic solvent unlike conventional liposomes. The physiological properties of these liposomes such as size, shape, and the membrane fluidity can be controlled by changing the constituents and compositional ratios. 
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Devices, CA, USA). The IC 50 values of HL were determined from the concentration-dependency of HL on the cell viability ( Figure  1C, D) . The results are summarized in Table 1 . The IC 50 values of HL were lower than those of DMPC liposomes in the growth of DU145 and PC-3 cells. These results indicate that HL could be effective for inhibiting the growth of prostate cancer cells.
We next examined the induction of apoptosis by HL in prostate cancer cells with a confocal laser scanning microscope using TUNEL method [12, 15] . The results are shown in Figure 2A . The nuclei of all cells were stained by TOPRO-3 and exhibited red fluorescence. We observed DNA fragmentation of prostate cancer cells when treated with HL for 48 hrs. In regard to the TUNEL staining, green or yellow (overlay) fluorescence was observed in cells treated with HL, indicating the presence of nuclear condensation and fragmentation in apoptotic cells. In contrast, green (or yellow) fluorescence in the cells was not observed in the case of DMPC liposomes. These results demonstrated that HL could induce apoptosis toward prostate cancer cells. With the concentration employed in our experiments, contribution extent of C 12 (EO) 25 , the second component of HL, to apoptosis signaling may be limited [16, 17] , because C 12 (EO) 25 has been primarily considered to function for vesicle -fluidity and -uptake into cells [18, 19] .
We further analyzed the DNA contents of HL-treated cells by flow cytometry, which can detect the apoptotic cells [12, 20] .
The cells (5 × 10
4 cells/ml) were seeded in 6 well plates and left to adhere overnight. The cells were then incubated for 48 hrs in the presence or absence of HL. Then, the cells were washed with phosphate-buffered saline (PBS), resuspended in PBS containing 0.1% Triton X-100, treated with RNase A, and stained with propidium iodide (PI) (Molecular Probes, CA, USA). The DNA content of each cell was measured using a flow cytometer (Epics XL system II, Beckman Coulter, CA, USA). The treatment with HL induced a significant increase in the apoptotic DNA rate in DU145 and PC-3 cells ( Figure 2B, C) , indicating that HL induced apoptotic cell death in both cells. These results show that the inhibitory effects of HL were attained through the induction of apoptosis in the prostate cancer cells.
To investigate the apoptotic pathways induced by HL on DU145 and PC-3 cells, activation of caspase-3 by HL was examined using PhiPhiLux -G 1 D 2 substrate [21] . The results are shown in Figure 2D . It is worth noting that fluorescent intensity increased and cancer cells were dyed in green after the treatment with HL, indicating that HL induced apoptosis for prostate cancer cells through the activation of caspase-3.
In conclusion, HL inhibited for the first time the growth of DU145 and PC-3 human prostate cells through the induction of apoptosis in vitro. This study suggests that HL could be a promising novel nanomedicinal agent for the treatment of prostate cancer. Data are the mean ± S.E. (n= 4) from three independent experiments.
